Identification of potent pyrazole based APELIN receptor (APJ) agonists
摘要:
The apelinergic system comprises the apelin receptor and its cognate apelin and elabela peptide ligands of various lengths. This system has become an increasingly attractive target for pulmonary and cardiometabolic diseases. Small molecule regulators of this receptor with good drug-like properties are needed. Recently, we discovered a novel pyrazole based small molecule agonist 8 of the apelin receptor (EC50 = 21.5 mu M, K-i = 5.2 mu M) through focused screening which was further optimized to initial lead 9 (EC50 = 0.800 mu M, K-i = 1.3 mu M). In our efforts to synthesize more potent agonists and to explore the structural features important for apelin receptor agonism, we carried out structural modifications at N1 of the pyrazole core as well as the amino acid side-chain of 9. Systematic modifications at these two positions provided potent small molecule agonists exhibiting EC50 values of < 100 nM. Recruitment of beta-arrestin as a measure of desensitization potential of select compounds was also investigated. Functional selectivity was a feature of several compounds with a bias towards calcium mobilization over beta-arrestin recruitment. These compounds may be suitable as tools for in vivo studies of apelin receptor function.
[EN] BENZOTRIAZEPINONE DERIVATIVES<br/>[FR] DERIVES DE BENZOTRIAZEPINONE
申请人:JAMES BLACK FOUNDATION
公开号:WO2006129120A9
公开(公告)日:2007-03-22
[EN] The present invention is concerned with benzotriazepinone derivatives, their intermediates, uses thereof and processes for their production. In particular, the present invention relates to parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrp) receptor ligands, (PTH-l or PTH/PTHrp receptor ligands). The invention also relates to methods of preparing such ligands and to compounds which are useful as intermediates in such methods. [FR] La présente invention concerne des dérivés de benzotriazépinone, leurs produits intermédiaires, leurs utilisations et des procédés pour leur production. Plus particulièrement, la présente invention concerne des ligands des récepteurs de l'hormone parathyroïdienne (PTH) et de la protéine apparentée à l'hormone parathyroïdienne (PTHrp) (ligands des récepteurs PTH-1 ou des récepteurs de la PTH/PTHrp). L'invention concerne également des procédés de préparation de ces ligands ainsi que des composés utiles comme produits intermédiaires dans ces procédés.
Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles
作者:Ramani R. Ranatunge、Michael Augustyniak、Upul K. Bandarage、Richard A. Earl、James L. Ellis、David S. Garvey、David R. Janero、L. Gordon Letts、Allison M. Martino、Madhavi G. Murty、Stewart K. Richardson、Joseph D. Schroeder、Matthew J. Shumway、S. William Tam、A. Mark Trocha、Delano V. Young
DOI:10.1021/jm030276s
日期:2004.4.1
The synthesis of a series of novel pyrazoles containing a nitrate (ONO(2)) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that pyrazole ring substituents play an important role in COX-2 selective inhibition, such that a cycloalkyl pyrazole (6b) was found to be a potent and selective COX-2
Identification of potent pyrazole based APELIN receptor (APJ) agonists
作者:Sanju Narayanan、Vineetha Vasukuttan、Sudarshan Rajagopal、Rangan Maitra、Scott P. Runyon
DOI:10.1016/j.bmc.2019.115237
日期:2020.2
The apelinergic system comprises the apelin receptor and its cognate apelin and elabela peptide ligands of various lengths. This system has become an increasingly attractive target for pulmonary and cardiometabolic diseases. Small molecule regulators of this receptor with good drug-like properties are needed. Recently, we discovered a novel pyrazole based small molecule agonist 8 of the apelin receptor (EC50 = 21.5 mu M, K-i = 5.2 mu M) through focused screening which was further optimized to initial lead 9 (EC50 = 0.800 mu M, K-i = 1.3 mu M). In our efforts to synthesize more potent agonists and to explore the structural features important for apelin receptor agonism, we carried out structural modifications at N1 of the pyrazole core as well as the amino acid side-chain of 9. Systematic modifications at these two positions provided potent small molecule agonists exhibiting EC50 values of < 100 nM. Recruitment of beta-arrestin as a measure of desensitization potential of select compounds was also investigated. Functional selectivity was a feature of several compounds with a bias towards calcium mobilization over beta-arrestin recruitment. These compounds may be suitable as tools for in vivo studies of apelin receptor function.